Regulation of Transcription and Translation by Human Polyomaviruses

人类多瘤病毒的转录和翻译调控

基本信息

  • 批准号:
    8768850
  • 负责人:
  • 金额:
    $ 22.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-06-01 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Some members of the Polyomaviridae induce tumors in laboratory animals or in their natural hosts. In these cases, tumorigenesis in animals or transformation in cell culture requires the expression of one or more viral proteins called tumor antigens. The monkey virus SV40 and its close relatives BKV and JCV encode a large tumor antigen (LT) that acts as the main oncoprotein. Transformation and tumorigenesis induced by SV40 has been studied extensively and requires the interaction of LT with three types of cellular proteins: (1) the Rb-proteins (pRb, p107, and p130), hsc70, and p53. The association of SV40 LT with Rb-proteins, coupled with the action of hsc70, triggers E2F-dependent transcription of cell cycle genes and this action is sufficient to drive quiescent cells to proliferate. SV40 LT als binds to the DNA-binding domain of the cellular tumor suppressor p53 and thus inhibits its ability to bind and activate the promoters of p53-responsive genes. Consequently, the expression of cell-cycle arrest or cell death-inducing proteins is blocked. Like SV40, the LTs encoded by the human polyomaviruses BKV and JCV also bind and inhibit Rb-proteins and p53. However, these LTs induce transformation much less efficiently than SV40 LT. Several studies have suggested that the weaker transformation seen by BKV and JCV is due to lower transcription from the viral promoters. We have compared the transforming abilities of the SV40, BKV, and JCV LTs by driving their expression from the same common heterologous promoter. While BKV and JCV LTs accumulated to much lower steady state levels than SV40 LT, all three LTs were equally capable of disrupting the pRb pathway and inducing cell proliferation. However, BKV and JCV LTs transformed much less efficiently than SV40 LT in a number of assays. The amount of p53 - presumably bound and inactivated by each LT- varied considerably in each case and correlated to the amount of each specific LT present. We thus hypothesize that the increased transformation induced by SV40 is explained by a "gain-of-function" attributed to LT-p53 complexes. We predict that LT does not simply block the expression of p53-dependent genes - preventing p53 association with promoters - but that it also uses the p53 activation domain to stimulate the transcription of cellular genes thus contributing positively to transformation. We will test this hypothesis by a series of p53 ChIP-seq experiments. We also found that SV40 LT increases and controls the translation of the regulators CBP/p300, a function previously unknown to LT molecules. Because all SV40, BKV and JCV LT share a high degree of homology, we hypothesize that translational control is a common property of polyoma LTs. We will test this hypothesis by performing RNA-seq experiments on ribosome associated mRNAs. These studies will fill important gaps in our understanding of polyomavirus-induced tumorigenesis.
描述(申请人提供):多核病毒科的一些成员在实验动物或其自然宿主中诱发肿瘤。在这些情况下,动物的肿瘤形成或细胞培养中的转化需要一种或多种称为肿瘤抗原的病毒蛋白的表达。猴病毒SV40及其近亲BKV和JCV编码一种作为主要癌蛋白的大肿瘤抗原(LT)。SV40诱导的转化和肿瘤发生已经得到了广泛的研究,需要LT与三种类型的细胞蛋白相互作用:(1)Rb蛋白(pRb、p107和p130)、hsc70和p53。SV40LT与Rb蛋白的结合,再加上hsc70的作用,触发了细胞周期基因依赖于E2F的转录,这一作用足以驱动静止的细胞增殖。SV40 LT ALS与细胞肿瘤抑制基因P53的DNA结合域结合,从而抑制其结合和激活P53反应基因启动子的能力。因此,细胞周期停滞或细胞死亡诱导蛋白的表达被阻断。与SV40一样,人类多瘤病毒BKV和JCV编码的LTS也结合并抑制RB蛋白和P53。然而,这些LT诱导转化的效率比SV40 LT低得多。一些研究表明,BKV和JCV的较弱转化是由于病毒启动子转录较低所致。我们通过驱动SV40、BKV和JCV LTS在同一共同的异源启动子上的表达来比较它们的转化能力。虽然BKV和JCV LTS的稳态水平比SV40 LT低得多,但这三种LT都有同样的能力扰乱PRB途径并诱导细胞增殖。然而,在许多检测中,BKV和JCV LTS的转化效率远远低于SV40 LT。每个LT可能结合和失活的P53的量在每个病例中都有很大的不同,并且与每个特定LT的量相关。因此,我们假设SV40诱导的转化增加是由LT-P53复合体的“功能增益”来解释的。我们预测LT不会简单地阻止P53依赖基因的表达--阻止P53与启动子的关联--它还利用P53激活结构域刺激细胞基因的转录,从而对转化做出积极贡献。我们将通过一系列的p53芯片序列实验来验证这一假设。我们还发现,SV40 LT增加并控制调节因子CBP/p300的翻译,这是LT分子以前未知的功能。因为所有的SV40、BKV和JCV LT都有很高的同源性,我们假设翻译控制是多发性LTS的共同特征。我们将通过对核糖体相关的mRNAs进行RNA-SEQ实验来检验这一假设。这些研究将填补我们对多瘤病毒诱导的肿瘤发生的理解的重要空白。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES M PIPAS其他文献

JAMES M PIPAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES M PIPAS', 18)}}的其他基金

Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10401454
  • 财政年份:
    2020
  • 资助金额:
    $ 22.06万
  • 项目类别:
Analysis of cellular factors limiting productive JC virus infections
限制生产性 JC 病毒感染的细胞因素分析
  • 批准号:
    10312804
  • 财政年份:
    2020
  • 资助金额:
    $ 22.06万
  • 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10030247
  • 财政年份:
    2020
  • 资助金额:
    $ 22.06万
  • 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10196991
  • 财政年份:
    2020
  • 资助金额:
    $ 22.06万
  • 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10621762
  • 财政年份:
    2020
  • 资助金额:
    $ 22.06万
  • 项目类别:
Exploring viral infection with single cell transcriptomics
用单细胞转录组学探索病毒感染
  • 批准号:
    9285734
  • 财政年份:
    2016
  • 资助金额:
    $ 22.06万
  • 项目类别:
Exploring viral infection with single cell transcriptomics
用单细胞转录组学探索病毒感染
  • 批准号:
    9167182
  • 财政年份:
    2016
  • 资助金额:
    $ 22.06万
  • 项目类别:
Regulation of cellular functions by two human Polyomaviruses
两种人类多瘤病毒对细胞功能的调节
  • 批准号:
    9088664
  • 财政年份:
    2016
  • 资助金额:
    $ 22.06万
  • 项目类别:
Regulation of Transcription and Translation by Human Polyomaviruses
人类多瘤病毒的转录和翻译调控
  • 批准号:
    8849838
  • 财政年份:
    2014
  • 资助金额:
    $ 22.06万
  • 项目类别:
Searching Environmental Metagenomes for Novel Infectious Cancer Agents (PQ12)
寻找环境宏基因组寻找新型传染性癌症病原体(PQ12)
  • 批准号:
    8382024
  • 财政年份:
    2012
  • 资助金额:
    $ 22.06万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了